CLOROX CO /DE/|4Nov 5, 6:59 PM ET

Bailey William S 4

4 · CLOROX CO /DE/ · Filed Nov 5, 2020

Form 4

Period: 2020-11-03

SVP - Corporate Business Dev

Transactions

Exercise/Conversion
Stock Option (Right to Buy)
2020-11-03−3,434→ 10,303 total
Exercise: $155.54From: 2020-09-17Exp: 2029-09-17→ Common Stock (3,434 underlying)
Exercise/Conversion
Common Stock
2020-11-03$151.85/sh+3,080$467,698→ 24,463 total
Exercise/Conversion
Common Stock
2020-11-03$123.09/sh+4,775$587,755→ 13,447 total
Sale
Common Stock
2020-11-03$212.47/sh−15,114$3,211,263→ 9,349 total
Exercise/Conversion
Stock Option (Right to Buy)
2020-11-03−4,775→ 0 total
Exercise: $123.09From: 2017-09-13Exp: 2026-09-13→ Common Stock (4,775 underlying)
Exercise/Conversion
Common Stock
2020-11-03$135.57/sh+4,502$610,336→ 17,949 total
Exercise/Conversion
Common Stock
2020-11-03$155.54/sh+3,434$534,124→ 21,383 total
Exercise/Conversion
Stock Option (Right to Buy)
2020-11-03−4,502→ 4,503 total
Exercise: $135.57From: 2018-09-12Exp: 2027-09-12→ Common Stock (4,502 underlying)
Exercise/Conversion
Stock Option (Right to Buy)
2020-11-03−3,080→ 6,160 total
Exercise: $151.85From: 2019-09-18Exp: 2028-09-18→ Common Stock (3,080 underlying)

Footnotes (2)

[F1]This transaction was executed in multiple trades at prices ranging from $212.33 to $212.93. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
[F2]Includes 68 shares acquired pursuant to a dividend reinvestment feature of the Company's Stock Incentive Plan.

Documents

1 file